Intercept Pharma (ICPT) Receives a Rating Update from a Top Analyst

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Intercept Pharma (ICPT), with a price target of $149. The company’s shares closed yesterday at $87.57.

According to, Baral is a top 100 analyst with an average return of 27.3% and a 52.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intercept Pharma with a $173.43 average price target, representing a 98.0% upside. In a report issued on April 28, Oppenheimer also assigned a Buy rating to the stock with a $170 price target.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $88.01 million. In comparison, last year the company had a GAAP net loss of $81.59 million.

Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year. Last month, Srinivas Akkaraju, a Director at ICPT bought 3,500 shares for a total of $85,660.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts